STOCK TITAN
  1. Home
  2. News
  3. BLTE

Belite Bio, Inc American Depositary Shares - BLTE STOCK NEWS

Welcome to our dedicated page for Belite Bio American Depositary Shares news (Ticker: BLTE), a resource for investors and traders seeking the latest updates and insights on Belite Bio American Depositary Shares stock.

Belite Bio, Inc. (NASDAQ: BLTE) is a clinical-stage biopharmaceutical company based in San Diego, California. Specializing in the development of novel therapeutics for untreatable age-related metabolic and degenerative retinal diseases, Belite Bio targets conditions such as macular degeneration, liver disease, and diabetes.

The company's flagship product, lbs-008 (Tinlarebant), is developed using its proprietary anti-RBP4 technology platform. Tinlarebant is currently in a Phase I clinical trial for dry age-related macular degeneration (AMD) and its juvenile form, Stargardt disease (STGD1). Both diseases involve retinal degeneration that can lead to permanent blindness. Tinlarebant has been granted orphan drug status in the U.S. and Europe, as well as rare pediatric disease status in the U.S.

Recent Achievements:

  • Completed Phase 2 trial of Tinlarebant in childhood-onset Stargardt Disease, demonstrating promising results in slowing retinal lesion growth and stabilizing visual acuity.
  • Initiated Phase III trials for GA and Stargardt disease, with enrollment completed for the Stargardt trial.
  • Received positive results and feedback during presentations at major ophthalmology conferences.

Belite Bio is currently conducting the DRAGON trial and the PHOENIX trial, targeting different stages of these degenerative diseases. The company remains focused on its mission to deliver novel, oral therapies for eye diseases with significant unmet medical needs. Financially, Belite Bio reported strong liquidity with $95.5 million in cash and U.S. Treasury bills as of March 31, 2024, following a successful $25 million registered direct offering in April 2024.

Looking ahead, the company plans to continue its clinical trials and further the development of its pipeline products, while maintaining a strong balance sheet. Investors should note the potential tax implications related to the company's classification under U.S. tax laws.

For more information, follow Belite Bio on Twitter, Instagram, LinkedIn, and Facebook, or visit their website at www.belitebio.com.

News

Belite Bio Announces $25 Million Registered Direct Offering

Rhea-AI Summary
Belite Bio, a clinical-stage biopharmaceutical company, announced a $25 million registered direct offering with an institutional investor. The offering includes the purchase and sale of 651,380 American Depositary Shares at $38.38 per ADS, along with warrants to purchase additional ADSs. The closing of the offering is imminent.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.61%
Tags
offering
-
News

Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan

Rhea-AI Summary
Belite Bio, Inc. announces positive results from a Phase 2 trial of Tinlarebant in treating Stargardt Disease and Geographic Atrophy. A pivotal global Phase 3 trial ('DRAGON') has been completed, with promising interim data expected in 4Q 2024. Tinlarebant has received Orphan Drug Designation in Japan and is also being studied in a global Phase 3 trial for Geographic Atrophy ('PHOENIX').
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.41%
Tags
clinical trial
-
News

Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website

Rhea-AI Summary
Belite Bio, Inc (BLTE) released its annual report on Form 20-F for the year ended December 31, 2023. The report includes audited financial statements and can be accessed on the company's website. Shareholders can request a free hard copy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.47%
Tags
none
News

Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Rhea-AI Summary
Belite Bio, Inc. announces positive results from Phase 2 trial of Tinlarebant in Stargardt Disease patients, completion of enrollment for Phase 3 trials, and strong financial position with $88.2 million in cash. The company is focused on developing oral therapies for eye diseases with significant unmet medical needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.47%
Tags
earnings
-
News

Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial Results

Rhea-AI Summary
Belite Bio, Inc (BLTE) will host a webcast on March 12, 2024, to discuss financial results and business updates for Q4 and full year 2023, focusing on therapeutics for degenerative retinal diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
conferences earnings
-
News

Belite Bio to Participate in the Leerink Partners Global Biopharma Conference

Rhea-AI Summary
Belite Bio, Inc. (BLTE) to participate in Leerink Partners Global Biopharma Conference, hosting a fireside chat on degenerative retinal diseases. Webcast available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.14%
Tags
conferences
News

Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Rhea-AI Summary
Belite Bio, Inc. (BLTE) will participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference and conduct a virtual presentation on February 14, 2024. The company focuses on developing therapeutics for degenerative retinal diseases with unmet medical needs. The webcast of the presentation can be accessed on the investor relations section of the Belite Bio website. The replay will be available for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.34%
Tags
conferences
-
News

Belite Bio to Participate in the Benchmark Company’s Upcoming Discovery One-on-One Investor Conference

Rhea-AI Summary
Belite Bio, Inc (NASDAQ: BLTE) will participate in the Benchmark Company’s 12th Annual Discovery One-on-One Investor Conference on December 7, 2023, in New York City. The company focuses on developing therapeutics for degenerative retinal diseases with unmet medical needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.1%
Tags
conferences
-
News

Belite Bio to Participate in the BTIG Ophthalmology Day

Rhea-AI Summary
Belite Bio, Inc. (NASDAQ: BLTE) to Participate in BTIG Ophthalmology Day Event
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.74%
Tags
conferences
News

Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial Results

Rhea-AI Summary
Belite Bio, Inc (NASDAQ: BLTE) announced the completion of enrollment in the pivotal Phase 3 “DRAGON” trial for Tinlarebant in adolescent Stargardt disease with 104 subjects enrolled across 11 countries. The company also dosed the first subject in the pivotal global Phase 3 “PHOENIX” trial in Geographic Atrophy. Tinlarebant continues to be safe and well tolerated, showing promising results in slowing expansion of autofluorescence, reducing incident atrophic retinal lesion growth rate, and stabilizing visual acuity up to 24-months in Phase 2 STGD1 trial. Interim Phase 3 safety and efficacy data from the “DRAGON” trial is expected in 2H 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.61%
Tags
earnings

FAQ

What is the current stock price of Belite Bio American Depositary Shares (BLTE)?

The current stock price of Belite Bio American Depositary Shares (BLTE) is $64.12 as of December 20, 2024.

What is the market cap of Belite Bio American Depositary Shares (BLTE)?

The market cap of Belite Bio American Depositary Shares (BLTE) is approximately 1.9B.

What is the focus of Belite Bio, Inc.?

Belite Bio focuses on developing novel therapeutics for degenerative retinal diseases and age-related metabolic diseases such as macular degeneration, liver disease, and diabetes.

What are Belite Bio's main products?

Belite Bio's main product is Tinlarebant (lbs-008), targeting dry AMD and Stargardt disease. It is currently in Phase I and Phase II clinical trials.

What recent achievements has Belite Bio made?

Belite Bio has completed Phase 2 trials for Tinlarebant in Stargardt Disease, initiated Phase III trials, and secured significant funding for continued research and development.

What are the financial highlights of Belite Bio?

As of March 31, 2024, Belite Bio had $95.5 million in cash and U.S. Treasury bills, and successfully raised $25 million in April 2024 through a direct offering.

What is Tinlarebant?

Tinlarebant (lbs-008) is an oral, potent, once-daily retinol binding protein 4 (RBP4) antagonist designed to decrease RBP4 levels in the blood, reducing vitamin A delivery to the eye.

What designations has Tinlarebant received?

Tinlarebant has received orphan drug status in the U.S. and Europe, as well as rare pediatric disease status in the U.S.

What clinical trials are currently ongoing at Belite Bio?

Belite Bio is conducting the DRAGON and PHOENIX trials, targeting various stages of degenerative retinal diseases.

How does Tinlarebant work?

Tinlarebant works by decreasing RBP4 levels in the blood, reducing vitamin A delivery to the eye without disrupting its delivery to other tissues.

Where can I find more information about Belite Bio?

More information about Belite Bio can be found on their website at www.belitebio.com or on their social media pages on Twitter, Instagram, LinkedIn, and Facebook.

What are the potential tax implications for U.S. investors?

Belite Bio may be classified as a passive foreign investment company (PFIC), which could have adverse U.S. federal income tax consequences for U.S. securityholders. Investors should consult their tax advisors.

Stock BLTE logo
Belite Bio, Inc American Depositary Shares

Nasdaq:BLTE

BLTE Rankings

#1992 Ranked by Market Cap
N/A Ranked by Dividends

BLTE Stock Data

1.93B
12.67M
58.6%
0.49%
0.78%
Biotechnology
Healthcare
Link
United States of America
San Diego